drugset / Trial / NCT02577848

GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

NCT02577848

Unknown 90 enrolled Chinese PLA General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).

Timeline

Start
2015-10
Primary completion
2016-10
Completion
2016-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous

Indications